# VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19

> **NCT05084755** · — · TERMINATED · sponsor: **AstraZeneca** · enrollment: 4 (actual)

## Conditions studied

- Prevention of Infectious Disease Caused by SARS-CoV-2

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05084755
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-11
- **Primary completion:** 2022-09-16
- **Final completion:** 2022-09-16
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** In Japan, the government purchases VAXZEVRIA and distributes it to medical institutions. Based on Japan VAXZEVRIA vaccination plan, the last vaccination day was Sep. 30, 2022. So it was difficult to continue this study.
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05084755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05084755, "VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05084755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*